Published in Biochim Biophys Acta on January 31, 2009
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res (2011) 1.47
Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist (2011) 1.27
BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg (2012) 1.23
SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med (2012) 1.18
Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology (2011) 1.13
Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery (2010) 1.00
The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget (2010) 0.98
Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene (2013) 0.97
BRAF mutations in thyroid tumors from an ethnically diverse group. Hered Cancer Clin Pract (2012) 0.92
Lessons from mouse models of thyroid cancer. Thyroid (2009) 0.90
Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. Oncotarget (2014) 0.86
Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas. Invest New Drugs (2013) 0.86
Current concepts and future directions in differentiated thyroid cancer. Clin Biochem Rev (2010) 0.85
Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer (2015) 0.85
Genetics and epigenetics of sporadic thyroid cancer. Mol Cell Endocrinol (2013) 0.85
Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? Front Endocrinol (Lausanne) (2012) 0.84
Human variation databases. Database (Oxford) (2010) 0.84
Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg (2010) 0.82
Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma. World J Surg Oncol (2013) 0.82
Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer. Surgery (2013) 0.81
BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China. World J Surg Oncol (2012) 0.79
The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma. Thyroid (2014) 0.78
Expression Profiling of a Human Thyroid Cell Line Stably Expressing the BRAFV600E Mutation. Cancer Genomics Proteomics (2016) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2006) 12.23
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol (2006) 6.57
Differential regulation and properties of MAPKs. Oncogene (2007) 6.36
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab (2008) 5.94
BRAF mutation in thyroid cancer. Endocr Relat Cancer (2005) 5.65
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev (2007) 5.21
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci U S A (1983) 4.82
Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med (2008) 4.39
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer (2006) 3.83
BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst (2006) 3.61
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab (2008) 3.38
Integrating signals from RTKs to ERK/MAPK. Oncogene (2007) 3.28
Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid (2004) 2.83
MAP kinases and the control of nuclear events. Oncogene (2007) 2.74
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res (2008) 2.57
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene (2003) 2.56
Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol (2005) 2.51
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res (2003) 2.44
Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab (2003) 2.44
A cohort study of thyroid cancer and other thyroid diseases after the chornobyl accident: thyroid cancer in Ukraine detected during first screening. J Natl Cancer Inst (2006) 2.37
The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg (2007) 2.36
Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res (2006) 2.31
Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J (2000) 2.17
BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res (2008) 2.03
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett (2004) 2.00
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene (2005) 1.99
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 1.95
RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology (2006) 1.85
BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer (2008) 1.83
New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol (2007) 1.74
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res (2005) 1.71
Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer (2007) 1.69
Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta (2007) 1.64
Raf: a strategic target for therapeutic development against cancer. J Clin Oncol (2005) 1.63
Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch (2005) 1.62
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.56
BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell (2003) 1.55
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest (1992) 1.52
Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res (2004) 1.47
BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res (2006) 1.43
Epidemiology and primary prevention of thyroid cancer. Thyroid (2002) 1.41
The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) (2005) 1.35
A pooled analysis of case-control studies of thyroid cancer: cigarette smoking and consumption of alcohol, coffee, and tea. Cancer Causes Control (2003) 1.31
BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol (2004) 1.27
Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther (2007) 1.26
Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females. Cancer Epidemiol Biomarkers Prev (1999) 1.23
Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab (2005) 1.20
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol (2004) 1.20
Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein. Oncogene (2006) 1.18
Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci (2002) 1.17
BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol (2006) 1.12
Targeting BRAF in thyroid cancer. Br J Cancer (2006) 1.08
The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol (2004) 1.07
Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther (2007) 1.04
New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer (2007) 1.02
Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol (2007) 1.00
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases. Cancer (2007) 0.98
Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell (2004) 0.98
Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid (2007) 0.98
AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res (2006) 0.95
BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch (2004) 0.95
Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab (2008) 0.90
Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot. World J Surg (2008) 0.84
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
Preoperative evaluation of thyroid nodules with 18FDG-PET/CT. Surgery (2005) 1.76
Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology (2008) 1.56
A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid (2009) 1.53
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res (2011) 1.47
Carcinoid tumors in the breast. Am J Surg (2006) 1.41
Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res (2004) 1.31
Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J (2009) 1.29
Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist (2011) 1.27
AACE/ACE disease state commentary: molecular diagnostic testing of thyroid nodules with indeterminate cytopathology. Endocr Pract (2014) 1.24
Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology (2011) 1.13
Controversies in the surgical management of sigmoid diverticulitis. J Gastrointest Surg (2007) 1.11
Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg (2008) 1.09
Biologic versus nonbiologic mesh in ventral hernia repair: a systematic review and meta-analysis. World J Surg (2014) 1.07
Ultrasound-guided percutaneous thyroid nodule core biopsy: clinical utility in patients with prior nondiagnostic fine-needle aspirate. Thyroid (2012) 1.03
Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun (2003) 1.02
Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery (2010) 1.00
SAGES guidelines for minimally invasive treatment of adrenal pathology. Surg Endosc (2013) 0.99
BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery (2012) 0.99
A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res (2009) 0.99
Hemorrhagic cholecystitis simulating gallbladder carcinoma. J Ultrasound Med (2004) 0.99
Diagnosis and management of pheochromocytoma. Curr Probl Surg (2014) 0.99
The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget (2010) 0.98
Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin Cancer Res (2007) 0.97
Clinical and cytological features predictive of malignancy in thyroid follicular neoplasms. Thyroid (2010) 0.96
Best cases from the AFIP: paraganglioma of the organs of Zuckerkandl. Radiographics (2003) 0.96
The thyroid incidentaloma: an increasingly frequent consequence of radiologic imaging. Semin Ultrasound CT MR (2005) 0.95
The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1. Blood (2013) 0.93
Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res (2005) 0.93
Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res (2005) 0.92
Thyroid surgery in octogenarians is associated with higher complication rates. Surgery (2009) 0.92
Management of thyroid nodules with atypical cytology on fine-needle aspiration biopsy. Ann Surg Oncol (2012) 0.91
Summary statement: utility of molecular marker testing in thyroid cancer. Surgery (2010) 0.90
Hyalinizing trabecular adenoma--an uncommon thyroid tumor frequently misdiagnosed as papillary or medullary thyroid carcinoma. Am J Surg (2007) 0.89
Thyroid incidentalomas: a new epidemic. Curr Surg (2004) 0.88
Accuracy of 4-dimensional computed tomography in poorly localized patients with primary hyperparathyroidism. Surgery (2010) 0.88
Management of thyroid incidentalomas. Surg Clin North Am (2004) 0.88
Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration. J Surg Oncol (2012) 0.87
Resident/fellow assistance in the operating room for endocrine surgery in the era of fellowships. Surgery (2010) 0.85
Reliability of fine-needle aspiration for thyroid nodules greater than or equal to 4 cm. J Surg Res (2012) 0.85
Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. Cancer Lett (2006) 0.85
Angiogenesis in benign and malignant thyroid disease. Thyroid (2005) 0.84
Role of SPECT and SPECT/CT in the Surgical Treatment of Primary Hyperparathyroidism. Int J Mol Imaging (2011) 0.83
Medical and surgical risks in thyroid surgery: lessons from the NSQIP. Ann Surg Oncol (2011) 0.82
Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg (2010) 0.82
Bilaterality in papillary thyroid carcinoma: does it influence prognosis? Ann Surg Oncol (2012) 0.81
Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer. Surgery (2013) 0.81
No need to abandon unilateral parathyroid surgery. J Am Coll Surg (2012) 0.81
Multiple signaling is involved in endostatin-mediated apoptosis in ECV 304 endothelial cells. Front Biosci (2005) 0.80
Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge. Ann Hematol (2015) 0.80
Diagnostic yield of nondiagnostic thyroid nodules is not altered by timing of repeat biopsy. Thyroid (2012) 0.80
Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery. Int J Colorectal Dis (2009) 0.80
Natural history of perianal Crohn's disease after fecal diversion. Inflamm Bowel Dis (2014) 0.79
The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma. Thyroid (2014) 0.78
Case records of the Massachusetts General Hospital: Case 38-2010: a 13-year-old girl with an enlarging neck mass. N Engl J Med (2010) 0.77
Voice issues and laryngoscopy in thyroid surgery patients. Surgery (2013) 0.77
Overcoming obstacles to setting up office-based ultrasound for evaluation of thyroid and parathyroid diseases. Laryngoscope (2011) 0.77
A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression. Thyroid (2014) 0.77
The Bethesda System for Reporting Thyroid Cytopathology: Proposed Modifications and Updates for the Second Edition from an International Panel. Acta Cytol (2016) 0.77
Antibiotic Treatment Induces Long-lasting Changes in the Fecal Microbiota that Protect Against Colitis. Inflamm Bowel Dis (2016) 0.76
Elective versus emergency surgery for ulcerative colitis: a National Surgical Quality Improvement Program analysis. Am J Surg (2013) 0.76
Laparoscopic adrenalectomy for pheochromocytoma. Curr Surg (2004) 0.76
When initial postexcision PTH level does not fall appropriately during parathyroidectomy: what to do next? World J Surg (2009) 0.76
Total proctocolectomy with ileoanal J-pouch reconstruction utilizing the hand-assisted laparoscopic approach. J Gastrointest Surg (2009) 0.76
Does preoperative total parenteral nutrition in patients with ulcerative colitis produce better outcomes? Int J Colorectal Dis (2012) 0.76
Restorative proctocolectomy: fertile ground for technical improvements? Inflamm Bowel Dis (2005) 0.75
The value of sestamibi scans. Surgery (2002) 0.75
Case records of the Massachusetts General Hospital. Case 10-2015. A 15-year-old girl with Graves’ disease and psychotic symptoms. N Engl J Med (2015) 0.75
Impact of perineal Crohn's disease on utilization of care in the absence of modifiable predictors of treatment failure. Int J Colorectal Dis (2014) 0.75
By the way, doctor. My mother recently had her gallbladder removed. The doctors say there are "surgical clips" in her. Are they supposed to be there and could they be the reason she is having pains in her side? Harv Health Lett (2003) 0.75
Image of the month: acute and chronic cholecystitis with abscess formation. Arch Surg (2006) 0.75
Parathyroid carcinoma and neurofibromatosis. Surgery (2008) 0.75
Surgical drains can be safely avoided in lateral neck dissections for papillary thyroid cancer. Am J Surg (2010) 0.75
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: TIMING OF MULTIPLE ENDOCRINE NEOPLASIA THYROIDECTOMY AND EXTENT OF CENTRAL NECK LYMPHADENECTOMY. Endocr Pract (2015) 0.75
Partial thyroidectomy: illustrated reflections for surgical residents. Curr Surg (2005) 0.75
Image of the month. Enterolithotomy. Arch Surg (2006) 0.75
Surgery for Graves' disease: a 25-year perspective. Am J Surg (2013) 0.75
By the way, doctor. I heard that human growth hormone can help people after surgery. Is that true? Harv Health Lett (2008) 0.75
Quantification of vascular endothelial cell apoptosis in vivo. Methods Enzymol (2008) 0.75
Risk estimator for adrenal tumor functionality. World J Surg (2014) 0.75
The gene expression and activity of calpains and the muscle wasting-associated ubiquitin ligases, atrogin-1 and MuRF1, are not altered in patients with primary hyperparathyroidism. Int J Mol Med (2006) 0.75
Comparison of primary and secondary breast cancers in adolescents and young adults. Cancer (2014) 0.75